Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
37 hedge funds and large institutions have $27.3M invested in Lumos Pharma, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 7 closing their positions.
8% less funds holding
Funds holding: 40 → 37 (-3)
15% less capital invested
Capital invested by funds: $32.1M → $27.3M (-$4.81M)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$950K |
| 2 |
MA
Minerva Advisors
Bala Cynwyd,
Pennsylvania
|
+$319K |
| 3 |
Millennium Management
New York
|
+$144K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$111K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$48.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.82M |
| 2 |
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Dallas,
Texas
|
-$500K |
| 3 |
DM
Deerfield Management
New York
|
-$331K |
| 4 |
Renaissance Technologies
New York
|
-$182K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$173K |
LUMO Hedge Fund Activity: Q3 2021 in Review
37 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2021, worth a combined $27.3M — down 15% from $32.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of LUMO and 4 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 7 added.
The largest buyer was Wells Fargo, adding an estimated $950K. The largest seller was Opaleye Management, exiting entirely with an estimated $3.82M sold.
- 37 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2021, down from 40 in Q2 2021.
- Funds reported $27.3M of Lumos Pharma, Inc. Common Stock stock for Q3 2021, down 15% quarter-over-quarter.
- 4 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2021 and 7 closed out, a net change of -3 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2021 was Wells Fargo, an estimated $950K added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q3 2021 was Opaleye Management, an estimated $3.82M sold.
Based on aggregated 13F filings for Q3 2021.